Dr. Posner has been engaged in clinical and translational research in cancers of the head and neck, HIV, and immunity for more than 40 years. He develops therapies to optimize treatment and advance early diagnosis and screening; he developed the TPF chemotherapy regimen for induction chemotherapy in head and neck cancer and curative rituximab therapy for Pemphigus Vulgaris. Dr. Posner’s current research is in the area of virally caused head and neck cancers. He is also investigating models that translate genetic findings into therapeutic treatment. Dr. Posner has served on numerous NCI study sections and review committees. He has authored over 250 peer reviewed clinical, laboratory and translational scientific publications covering cancer therapeutics, monoclonal antibodies and immunology, autoimmune disease, and infectious diseases.